Aimmune Therapeutics Announces Presentations at 2018 ACAAI Annual Scientific Meeting

Business Wire 8-Nov-2018 8:00 AM

— Oral Presentation on Data from Aimmune's Pivotal Phase 3 PALISADE Trial —

— Additional Oral and E-Poster Presentations on AR101, Peanut Allergy and Oral Immunotherapy —

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on AR101, oral immunotherapy and peanut allergy at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting, taking place November 15-19, 2018, in Seattle. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patients with peanut allergy.

Presentation details are as follows:

Oral Presentations

#A103: Burks et al., Age-Related Findings from the Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization (PALISADE) Study (Presenter: S. Tilles)Oral Abstracts Session 1B: Allergy Diagnostics & Immunotherapy1:00 – 2:30 p.m. PST (1:45 p.m.), Sunday, November 18Washington State Convention Center, Room 615-617

#A308: Sher et al., Application of Oral Immunotherapy (OIT) Clinical Trial Endpoints to a Real-World SettingOral Abstracts Session 3A: Food Allergy9:45 – 11:00 a.m. PST (10:15 a.m.), Monday, November 19Washington State Convention Center, Room 611-614

#A309: Lieberman et al., Increased Incidence and Prevalence of Peanut Allergy in Children and Adolescents in the United States (Presenting author: J. Sublett)Oral Abstracts Session 3A: Food Allergy9:45 – 11:00 a.m. PST (10:30 a.m.), Monday, November 19Washington State Convention Center, Room 611-614

#A313: Bird et al., Oral Desensitization to Peanut Using AR101 Peanut Oral Immunotherapy in a Roll-Over Safety Study ARC002Oral Abstracts Session 4B: Food Allergy; Other Airway Disorders11:15 a.m. – 12:30 p.m. PST (11:45 a.m.), Monday, November 19Washington State Convention Center, Room 615-617

E-Posters

#P310: Assa'ad et al.,Treatment Satisfaction with AR101 Peanut Allergy Oral Immunotherapy: A Mixed Methods StudyE-Posters Session 13:00 – 6:00 p.m. PST (4:40 p.m.), Friday, November 16Washington State Convention Center, Room 4ABCDE, Monitor 3

#P115: Chipps et al., Attitudes Among U.S.-Based Allergists and Immunologists About Immunotherapy, Peanut Exposure and Treatment (Presenting author: C. Ciaccio)E-Posters Session 511:30 a.m. – 1:00 p.m. (11:50 a.m.), Sunday, November 18Washington State Convention Center, Room 4ABCDE, Monitor 1

Aimmune will also host an evening Corporate Forum, "Five Things You Should Know About Peanut Allergy and Oral Immunotherapy," on Saturday, November 17.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing treatments for life-threatening food allergies. The company's Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune's first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA's Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age. Aimmune plans to submit regulatory filings for marketing approval of AR101 in the United States and Europe based on data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials. For more information, please see www.aimmune.com.

This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181108005298/en/